Curated News
By: NewsRamp Editorial Staff
August 08, 2025
Nutriband's AVERSA Fentanyl Patch Advances Toward FDA Review
TLDR
- Nutriband's AVERSA Fentanyl patch, with FDA meeting set for 2025, offers a competitive edge by targeting $80M-$200M in U.S. sales with its abuse-deterrent technology.
- Nutriband's AVERSA Fentanyl patch combines abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, aiming to prevent misuse while ensuring patient access through a detailed CMC review process.
- The development of AVERSA Fentanyl by Nutriband aims to reduce opioid abuse and accidental exposure, contributing to a safer healthcare environment for patients globally.
- Nutriband is pioneering the first abuse-deterrent opioid patch, AVERSA Fentanyl, protected by patents in 46 countries, marking a significant advancement in transdermal pharmaceutical technology.
Impact - Why it Matters
The development of an abuse-deterrent opioid patch like AVERSA Fentanyl is a critical advancement in the fight against the opioid crisis. By addressing the dual challenges of preventing abuse while ensuring access for patients in genuine need, this innovation has the potential to significantly reduce the risks associated with opioid use. The technology's broad patent protection and substantial market potential underscore its importance in the pharmaceutical industry and public health.
Summary
Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, has reached a significant milestone with its AVERSA(TM) Fentanyl patch, as the U.S. Food and Drug Administration schedules a Type C Meeting for September 18, 2025, to review its Chemistry, Manufacturing, and Controls plans. This innovative patch, which combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch, aims to address the critical issues of abuse, diversion, misuse, and accidental exposure, while ensuring patients in need retain access. With patents secured in 46 countries and peak annual U.S. sales potential estimated between $80 million to $200 million, AVERSA Fentanyl is poised to become the first abuse-deterrent opioid patch globally. For more details, visit https://ibn.fm/GGIyr.
Nutriband Inc. is at the forefront of developing transdermal pharmaceutical products, with AVERSA(TM) technology at its core, designed to prevent the abuse of drugs with potential for misuse. The company's efforts represent a significant step forward in pharmaceutical safety and patient care. Discover more about Nutriband and its groundbreaking work at www.nutriband.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband's AVERSA Fentanyl Patch Advances Toward FDA Review
